Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved..
Failure of pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine may occur despite perfect adherence, although this is uncommon. Failure results in breakthrough HIV infection. Delayed seroconversion associated with antiretroviral use may complicate the picture, causing uncertainties in interpreting adherence patterns for establishing the true cause of PrEP failure.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:94 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 94(2020) vom: 01. Mai, Seite 41-43 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Shui-Shan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
99YXE507IL |
|---|
| Anmerkungen: |
Date Completed 24.06.2020 Date Revised 24.06.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2020.03.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307615375 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307615375 | ||
| 003 | DE-627 | ||
| 005 | 20231225125942.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2020.03.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1025.xml |
| 035 | |a (DE-627)NLM307615375 | ||
| 035 | |a (NLM)32173577 | ||
| 035 | |a (PII)S1201-9712(20)30133-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Shui-Shan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.06.2020 | ||
| 500 | |a Date Revised 24.06.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Failure of pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine may occur despite perfect adherence, although this is uncommon. Failure results in breakthrough HIV infection. Delayed seroconversion associated with antiretroviral use may complicate the picture, causing uncertainties in interpreting adherence patterns for establishing the true cause of PrEP failure | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Antiretroviral | |
| 650 | 4 | |a HIV seroconversion | |
| 650 | 4 | |a PrEP failure | |
| 650 | 4 | |a Pre-exposure prophylaxis | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 650 | 7 | |a Emtricitabine |2 NLM | |
| 650 | 7 | |a G70B4ETF4S |2 NLM | |
| 700 | 1 | |a Anderson, Peter L |e verfasserin |4 aut | |
| 700 | 1 | |a Kwan, Tsz-Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Lui, Grace C Y |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Denise P C |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Ngai-Sze |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Krystal C K |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Teddy T N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 94(2020) vom: 01. Mai, Seite 41-43 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:94 |g year:2020 |g day:01 |g month:05 |g pages:41-43 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2020.03.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 94 |j 2020 |b 01 |c 05 |h 41-43 | ||